ストックスクリーナーアプリを入手
8.65
2.26%
-0.20
アフターアワーズ：
8.65
Climb Bio Inc (CLYM) 最新ニュース
CLYM Initiated Coverage by Mizuho -- Rating Set to Outperform - GuruFocus
Mizuho Securities Initiates Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $18 - Moomoo
Mizuho initiates Climb Bio stock coverage with outperform rating By Investing.com - Investing.com Australia
Mizuho initiates Climb Bio stock coverage with outperform rating - Investing.com
Climb Bio (CLYM) price target increased by 34.43% to 15.67 - MSN
CLYM Options Volatility — NASDAQ:CLYM - TradingView — Track All Markets
CLYM Options Chain — NASDAQ:CLYM - TradingView — Track All Markets
[PRE 14A] Climb Bio, Inc. Preliminary Proxy Statement - Stock Titan
Piper Sandler Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $23 - Moomoo
CLYM Stock Price, Quote & Chart | CLIMB BIO INC (NASDAQ:CLYM) - ChartMill
Climb Bio’s (CLYM) “Buy” Rating Reaffirmed at BTIG Research - Defense World
Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026 - Sahm
Income Plays: Does Climb Bio Inc offer margin of safety2026 Trade Ideas & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Climb Bio, Inc. to hold live R and D webcast on Budoprutug and CD19 opportunity - Traders Union
Growth Value: Is Climb Bio Inc currently under institutional pressure2026 Sector Moves & Technical Buy Zone Confirmation - baoquankhu1.vn
CLYM: BTIG Reiterates Buy Rating with $8 Target Price | CLYM Sto - GuruFocus
CLYM: BTIG Reiterates Buy Rating with $8 Target Price | CLYM Stock News - GuruFocus
Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy - Sahm
Climb Bio’s budoprutug receives FDA fast track for kidney disease By Investing.com - Investing.com Australia
BTIG reiterates Buy on Climb Bio stock after FDA Fast Track nod - Investing.com Canada
BTIG reiterates Buy on Climb Bio stock after FDA Fast Track nod By Investing.com - Investing.com South Africa
FDA grants fast track status to Climb Bio’s kidney disease drug By Investing.com - Investing.com South Africa
FDA grants fast track status to Climb Bio’s kidney disease drug - Investing.com India
Climb Bio (stock code: CLYM) announced today that the U.S. Food and Drug Administration (FDA) has granted its candidate drug Budoprutug Fast Track designation for the treatment of primary membranous nephropathy. - Bitget
Climb Bio Announces FDA Fast Track Designation For Budoprutug For The Treatment Of Primary Membranous Nephropathy - TradingView — Track All Markets
Climb Bio Announces FDA Fast Track Designation for - GlobeNewswire
Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight - Dailyhunt
Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight - GlobeNewswire Inc.
Climb Bio, Inc. 8-K Filing Details: Company Information, Address, and Stock Exchange Listing (April 2026) - Minichart
Climb Bio announces departure of finance SVP and appointment of new accounting officer By Investing.com - Investing.com South Africa
Climb Bio announces departure of finance SVP and appointment of new accounting officer - Investing.com
Climb Bio's recently appointed CFO is unlikely to make a significant impact—what truly matters is the clinical data. - Bitget
Climb Bio Consolidates Financial Leadership After SVP Departure - TipRanks
Climb Bio (CLYM) consolidates CFO and principal accounting officer roles - Stock Titan
Piper Sandler initiates coverage of Climb Bio (CLYM) with overweight recommendation - MSN
Climb Bio, Inc. (NASDAQ:CLYM) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Climb Bio, Inc.Common Stock (NQ: CLYM - The Chronicle-Journal
Climb Bio (NASDAQ:CLYM) Raised to Strong-Buy at B. Riley Financial - MarketBeat
B Riley Securities initiates coverage of Climb Bio (CLYM) with buy recommendation - MSN
B. Riley Securities Initiates Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $26 - Moomoo
B. Riley Financial Initiates Coverage on Climb Bio (NASDAQ:CLYM) - MarketBeat
B.Riley initiates Climb Bio stock with buy rating on kidney drug potential - Investing.com
B.Riley initiates Climb Bio stock with buy rating on kidney drug potential By Investing.com - Investing.com Australia
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):